{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Vo JB"],"funding":["The Young Women’s Breast Cancer Study is funded in part by Susan G. Komen and Breast Cancer Research Foundation","Cancer Prevention Fellowship Program at the National Cancer Institute","National Cancer Institute"],"pubmed_abstract":["Purpose
Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.Methods
Among 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.Results
Most women had stage I or I"],"journal":["Journal of cancer survivorship : research and practice"],"pagination":["189-197"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12906554"],"repository":["biostudies-literature"],"pubmed_title":["Association of cancer treatment with excess heart age among five-year young breast cancer survivors."],"pmcid":["PMC12906554"],"pubmed_authors":["Snow C","Schapira L","Poorvu PD","Kirkner G","Rosenberg S","Peppercorn JM","Vo JB","Gaither R","Borges VF","Come SE","Nohria A","Partridge AH","Tamimi RM","Zhang BX","Ruddy KJ"],"additional_accession":[]},"is_claimable":false,"name":"Association of cancer treatment with excess heart age among five-year young breast cancer survivors.","description":"Purpose
Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.Methods
Among 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.Results
Most women had stage I or I","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T00:08:10.227Z","creation":"2026-07-09T10:25:53.013Z"},"accession":"S-EPMC12906554","cross_references":{"pubmed":["39008138"],"doi":["10.1007/s11764-024-01645-9"]}}